Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor

@inproceedings{Minami2017NeutrophiltoLymphocyteRP,
  title={Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor},
  author={Seigo Minami and Yoshitaka Ogata and Shouichi Ihara and Suguru Yamamoto and Kiyoshi Komuta},
  booktitle={World journal of oncology},
  year={2017}
}
Background Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) have been demonstrated to be prognostic biomarkers in various cancers, including non-small cell lung cancer (NSCLC). However, little has been known about these two ratios for a specific population of NSCLC harboring active epidermal growth factor receptor (EGFR) mutation. Methods We retrospectively reviewed electrical medical records of 152 patients who met the following criteria: NSCLC harboring mutant… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL